An Investigational New Drug (IND) application is a regulatory submission made to the FDA by a sponsor seeking authorization to initiate clinical trials of an investigational drug, biologic, or gene therapy product in human subjects. An IND includes preclinical data, Chemistry, Manufacturing, and Controls (CMC) information, clinical trial protocols, and investigator information, and must demonstrate that the product is sufficiently safe to be tested in humans.
